Sign in
Taking peoplePhase 1/2

Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)

Key facts

Who runs it
Shanghai Mianyi Biopharmaceutical Co., Ltd.
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
60 people, planned
Started
26 Aug 2026
Expected to end
30 Dec 2029
Type of study
Interventional
Treatments tested
  • BBM-C101
Record updated
16 November 2026

Who can take part

Age
18 years to 55 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Histologically confirmed HPV16 and/or HPV18 associated HSIL
  • Colposcopy findings at screening at each study center must meet all of the following conditions: The colposcopy examination should be satisfactory and The ECC result must be negative
  • Women of childbearing potential must agree to use highly effective contraception together with their partner throughout the study and for at least 1 year after the first dose ; f and a serum pregnancy test within 7 days prior to enrollment must be negative
  • Willing to voluntarily participate in the study and provide written informed consent
  • In the opinion of the Investigator, the participant is expected to demonstrate good compliance and be able to complete all scheduled visits and follow-up assessments in accordance with the study protocol ; -

Who cannot take part

  • Participants who have received any treatment for HPV positivity or cervical HSIL prior to study drug
  • History of previous therapeutic HPV vaccination ( except for the licensed prophylactic HPV vaccines )
  • Participants who have used any local or systemic immunosuppressive agents prior to the first administration of BBM-C101 injection
  • Received any licensed vaccines within 2 weeks prior to study drug administration
  • Having participated in other clinical trials before signing the informed consent form, including studies involving investigational drugs or devices
  • Participants who have received any gene therapy treatment prior to screening, or plans to receive any other gene therapy treatment during the study period
  • Participants with unstable cardiovascular or cerebrovascular diseases, defined as clinical cardiovascular event (such as unstable angina, myocardial infarction, stroke, etc.) occurring within 3 months prior to screening; participants with severe uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg)
  • Active drug or alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirements
  • Major surgery or significant trauma within 4 weeks prior to the first dose
  • Participants with acute cervical inflammation or acute exacerbation of chronic cervical disease
  • Positive results were obtained in the tests for hepatitis C virus antibody, human immunodeficiency virus (HIV)
  • Participants with a history or diagnosis of autoimmune diseases, including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener's granulomatosis, Graves' disease, rheumatoid arthritis, hypophysitis , uveitis, autoimmune hepatitis, systemic sclerosis, autoimmune vasculitis, autoimmune neuropathy (Guillain-Barré syndrome), etc
  • Participants with active infections requiring systemic anti-infective therapy
  • Participants with a known history of malignant tumors in any organ/system (regardless of evidence of local recurrence or metastasis)
  • Participants with a history of severe allergic diseases ( e.g., allergy-related shock, dyspnea, angioedema) )
  • Any other conditions judged by the Investigator that may affect a participant's safety or compliance ; -
  • Participants with clinically significant abnormal values in laboratory tests during screening, as determined by the Investigator to increase risk to the participant's participation in the clinical trial . This includes, but is not limited to, any of the following:; White blood cell count < 3.0 × 10⁹/L; Hemoglobin < 90 g/L; Platelet < 100 × 10⁹/L; Aspartate aminotransferase or alanine aminotransferase > 2 × upper limit of normal (ULN); Total bilirubin > 1.5 × ULN; Creatinine > 1.5 × ULN
  • During screening, cytological or histopathological shows any of the following results: adenocarcinoma in situ (AIS), atypical glandular cells-favor neoplasia (AGC-FN), or invasive carcinoma
  • Participants who are unable or unwilling to undergo colposcopy, or have contraindications to colposcopy
  • Pregnant or breastfeeding (lactating)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this study is to learn about the safety, tolerability, immunogenicity and preliminary efficacy of BBM-C101 injection in patients with High-Grade Squamous Intraepithelial Lesion of the cervix.

Read full original descriptionShow less

This study include two phases: Phase I and Phase IIa .

The group in the trial

  • Arm of BBM-C101Treatment being tested

    Treatment: BBM-C101

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I/ IIa, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesions.
Criteria questions
Built from NCT07668960, who can take part
Record updated
16 November 2026